Lilly stands to gain from GlaxoSmithKline's woes

May 22, 2007
Eli Lilly and Co. could benefit from a recent New England Journal of Medicine report that Avandia, GlaxoSmithKline's diabetes drug, might heighten the risk of heart attacks by 43 percent, according to Forbes.

Lilly and a Japanese partner have developed Actos, which is similar to Avandia. However, unlike GlaxoSmithKline's drug, Actos doesn't make a big difference in cholesterol levels.
Source: XMLFULL/XMLFull2017.xml

Recent Articles by IBJ Staff

Comments powered by Disqus